These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22001144)

  • 1. Retrospective clinical analysis for drug rescue: for new indications or stratified patient groups.
    Cavalla D; Singal C
    Drug Discov Today; 2012 Feb; 17(3-4):104-9. PubMed ID: 22001144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase IV research by pharmaceutical companies.
    Hakkarainen H; Hattab JR; Venulet J
    Pharmacopsychiatry; 1984 Sep; 17(5):168-75. PubMed ID: 6494246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SMi's Conducting Clinical Trials in Europe.
    Jago C
    IDrugs; 2009 Dec; 12(12):754-9. PubMed ID: 19943216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacometrics 2020.
    Gobburu JV
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):151S-157S. PubMed ID: 20881229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development.
    Peck RW
    Drug Discov Today; 2007 Apr; 12(7-8):289-94. PubMed ID: 17395088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PhRMA survey on the conduct of first-in-human clinical trials under exploratory investigational new drug applications.
    Karara AH; Edeki T; McLeod J; Tonelli AP; Wagner JA
    J Clin Pharmacol; 2010 Apr; 50(4):380-91. PubMed ID: 20097935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Strategy of molecular drug design: hits, leads and drug candidates].
    Guo ZR
    Yao Xue Xue Bao; 2008 Sep; 43(9):898-904. PubMed ID: 19048779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of drug repositioning in the current pharmaceutical market.
    Tobinick EL
    Drug News Perspect; 2009 Mar; 22(2):119-25. PubMed ID: 19330170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptive trials receive boost.
    Jones D
    Nat Rev Drug Discov; 2010 May; 9(5):345-8. PubMed ID: 20414200
    [No Abstract]   [Full Text] [Related]  

  • 12. Predicting therapeutic efficacy - experimental pain in human subjects.
    Chizh BA; Priestley T; Rowbotham M; Schaffler K
    Brain Res Rev; 2009 Apr; 60(1):243-54. PubMed ID: 19168094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translational research in the pharmaceutical industry: from theory to reality.
    Sultana SR; Roblin D; O'Connell D
    Drug Discov Today; 2007 May; 12(9-10):419-25. PubMed ID: 17467579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opinion: anticipating change in drug development: the emerging era of translational medicine and therapeutics.
    Fitzgerald GA
    Nat Rev Drug Discov; 2005 Oct; 4(10):815-8. PubMed ID: 16224453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico repositioning of approved drugs for rare and neglected diseases.
    Ekins S; Williams AJ; Krasowski MD; Freundlich JS
    Drug Discov Today; 2011 Apr; 16(7-8):298-310. PubMed ID: 21376136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. If 'atypical' neuroleptics did not exist, it wouldn't be necessary to invent them: perverse incentives in drug development, research, marketing and clinical practice.
    Charlton BG
    Med Hypotheses; 2005; 65(6):1005-9. PubMed ID: 16182461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules.
    Luker T; Alcaraz L; Chohan KK; Blomberg N; Brown DS; Butlin RJ; Elebring T; Griffin AM; Guile S; St-Gallay S; Swahn BM; Swallow S; Waring MJ; Wenlock MC; Leeson PD
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5673-9. PubMed ID: 21852131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active-controlled, non-inferiority trials in oncology: arbitrary limits, infeasible sample sizes and uninformative data analysis. is there another way?
    Carroll KJ
    Pharm Stat; 2006; 5(4):283-93. PubMed ID: 17128427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.